Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing buntanetap for neurodegenerative diseases, announced that President and CEO Maria Maccecchini, Ph.D., will present at Fierce Biotech Week 2026 in Boston on May 13. The presentation will discuss the scientific basis for treating Alzheimer's disease as a multi-protein disorder and highlight Annovis' approach of targeting multiple neurotoxic proteins simultaneously through its lead drug candidate, buntanetap.
Buntanetap, an investigational once-daily oral therapy, inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. The drug is currently in a pivotal Phase 3 clinical trial.
The presentation at Fierce Biotech Week comes at a critical time for Alzheimer's research, as the field shifts toward combination therapies targeting multiple pathological pathways. Annovis' multi-protein approach offers a potential advantage over single-target treatments, which have shown limited efficacy in clinical trials. The company's strategy is based on growing evidence that Alzheimer's involves the accumulation of several neurotoxic proteins, not just amyloid beta.
Headquartered in Malvern, Pennsylvania, Annovis Bio is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). For more information, visit www.annovisbio.com.
The latest news and updates relating to ANVS are available in the company's newsroom at https://ibn.fm/ANVS.
